Scroll Back to Top

Graphical Summary: Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplification in non-small cell lung cancer

November 13, 2024

This one-page document summarizes our published manuscript in Frontiers in Oncology, where the PGDx elio tissue complete assay demonstrated 100% concordance with IHC, FISH and RNA profiling for the detection of ALK rearrangements in NSCLC.

Covering a 505-gene panel aligned to CDx and National Comprehensive Cancer Network® (NCCN®) guideline targets, the FDA-cleared, CE-IVD marked PGDx elio™ tissue complete assay is now available in our Baltimore, Geneva and Shanghai laboratories, as the Labcorp Tissue Complete service.